KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

BeOne Medicines (ONC) Short-Term Debt repayments: 2020-2025

Historic Short-Term Debt repayments for BeOne Medicines (ONC) over the last 3 years, with Jun 2025 value amounting to $102.9 million.

  • BeOne Medicines' Short-Term Debt repayments fell 34.69% to $102.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $980.0 million, marking a year-over-year increase of 134.97%. This contributed to the annual value of $704.2 million for FY2024, which is 127.48% up from last year.
  • According to the latest figures from Q2 2025, BeOne Medicines' Short-Term Debt repayments is $102.9 million, which was down 40.52% from $172.9 million recorded in Q1 2025.
  • BeOne Medicines' Short-Term Debt repayments' 5-year high stood at $546.7 million during Q4 2024, with a 5-year trough of $16.0 million in Q2 2021.
  • In the last 3 years, BeOne Medicines' Short-Term Debt repayments had a median value of $126.4 million in 2023 and averaged $161.2 million.
  • In the last 5 years, BeOne Medicines' Short-Term Debt repayments spiked by 1,575.76% in 2021 and then crashed by 60.78% in 2023.
  • Quarterly analysis of 5 years shows BeOne Medicines' Short-Term Debt repayments stood at $205.2 million in 2021, then skyrocketed by 32.37% to $271.7 million in 2022, then slumped by 44.78% to $150.0 million in 2023, then skyrocketed by 264.48% to $546.7 million in 2024, then slumped by 34.69% to $102.9 million in 2025.
  • Its Short-Term Debt repayments was $102.9 million in Q2 2025, compared to $172.9 million in Q1 2025 and $546.7 million in Q4 2024.